Evidence map›Paper›PMID 30623066›Full record

ArticleHealth science reports2018

Comparison of the Aptima HIV-1 Quant Dx assay with the COBAS AmpliPrep/COBAS TaqMan HIV-1 v2.0 Test for HIV-1 viral load quantification in plasma samples from HIV-1-infected patients.

Serena Longo, Isabella Bon, Giuseppina Musumeci, Alessia Bertoldi, Vanessa D'Urbano, Leonardo Calza, Maria Carla Re

Open access · goldAbstract read
In one paragraph

Article in Health science reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Performance evaluation of the Aptima HIV-1 RNA Quant assay on the Panther system using the standard and dilution protocols.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2020
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Serena LongoMicrobiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine University of Bologna Italy.ORCID 0000-0001-8595-1259
Isabella BonMicrobiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine University of Bologna Italy.ORCID 0000-0002-9433-5201
Giuseppina MusumeciMicrobiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine University of Bologna Italy.ORCID 0000-0003-0118-4537
Alessia BertoldiMicrobiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine University of Bologna Italy.ORCID 0000-0002-5929-2269
Vanessa D'UrbanoMicrobiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine University of Bologna Italy.ORCID 0000-0001-5575-1862
Leonardo CalzaClinics of Infectious Diseases, Department of Medical and Surgical Sciences St. Orsola-Malpighi Hospital, University of Bologna Italy.ORCID 0000-0002-1895-1504
Maria Carla ReMicrobiology Section of the Department of Experimental, Diagnostic and Specialty Medicine, School of Medicine University of Bologna Italy.ORCID 0000-0003-1486-9033
University of Bologna · ITIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsHIV-1 RNA viral load (VL) in plasma samples of HIV-1-positive patients is used to assess the level of viral replication, the risk of disease progression, and the response and efficacy to antiretroviral treatment. Knowing the performance of different tests for HIV-1 RNA detection is, therefore, important for clinical care. This study compared the performance of the recently introduced Aptima HIV-1 Quant Dx assay (Hologic, Inc) and the standard COBAS AmpliPrep/COBAS TaqMan HIV-1 v2.0 Test (CAP/CTM2) (Roche Molecular System, Inc) for HIV-1 RNA quantitation.

methodsAssay performance was assessed using 335 clinical samples, a standard HIV-1 low VL panel, and 2 diluted samples from well-characterized patients infected with different HIV-1 subtypes tested in 5 replicates over 3 days. All samples were tested on both assays to evaluate inter-assay agreement, both qualitatively and quantitively. Altogether, we evaluated assay sensitivity, linearity, accuracy, precision, repeatability, and reproducibility.

resultsAssay agreement for qualitative results in 335 clinical samples was fair (80.6%). Correlation of quantitative assay results (n = 164) was excellent (R

conclusionAptima-HIV-1 assay demonstrated sensitivity, accuracy, reproducibility, and precision for the detection and quantitation of HIV-1 RNA across a wide dynamic range of VLs. Its performance, together with full automation and high throughput, suggests that Aptima-HIV-1 could be a suitable assay for reliable monitoring of HIV-1 VL in patients undergoing treatment.

Indexed as

clinical samplesHIV‐1HIV‐1 RNA quantitationHIV‐1 subtypes

Identifiers

PMID30623066
PMCPMC6266574
OpenAlexW2792575508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.